DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Trisenox (Arsenic Trioxide) - Published Studies

 
 



Trisenox Related Published Studies

Well-designed clinical trials related to Trisenox (Arsenic Trioxide)

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. [2011.07]

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. [2010.11.11]

The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. [2009.08]

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. [2007.03.15]

[Clinical observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia] [2004.03.02]

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. [2003.06.15]

[An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid] [1999.02]

Well-designed clinical trials possibly related to Trisenox (Arsenic Trioxide)

Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. [2010.05]

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. [2004.04.13]

Other research related to Trisenox (Arsenic Trioxide)

Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. [2011.11.01]

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. [2011.09.01]

The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. [2011.09]

Arsenic trioxide re-sensitizes ERalpha-negative breast cancer cells to endocrine therapy by restoring ERalpha expression in vitro and in vivo. [2011.09]

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. [2011.08.11]

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. [2011.07.10]

Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. [2011.06]

Inorganic arsenic causes cell apoptosis in mouse cerebrum through an oxidative stress-regulated signaling pathway. [2011.06]

Synergic effect of 3'-azido-3'-deoxythymidine and arsenic trioxide in suppressing hepatoma cells. [2011.06]

Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. [2011.05]

Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. [2011.05]

Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. [2011.04]

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. [2011.03.15]

Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. [2011.02]

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. [2011.01.01]

[Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice]. [2011.01]

The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. [2011]

Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide. [2010.12.10]

Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme. [2010.10]

Arsenic trioxide combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice. [2010.10]

Synergistic cytotoxic effects of arsenic trioxide plus dithiothreitol on mice oral cancer cells. [2010.09]

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. [2010.08.20]

Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. [2010.08.12]

Arsenic trioxide combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice. [2010.08.03]

Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. [2010.08]

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. [2010.07]

Arsenic trioxide up-regulates Fas expression in human osteosarcoma cells. [2010.07]

Combination therapy with arsenic trioxide for hematological malignancies. [2010.07]

A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. [2010.06.01]

Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. [2010.06]

Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience. [2010.06]

Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. [2010.05.01]

Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. [2010.05]

Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival. [2010.05]

Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. [2010.05]

Chitin and chitosan as multipurpose natural polymers for groundwater arsenic removal and AS2O3 delivery in tumor therapy. [2010.04.28]

Antitumor effect and mechanisms of arsenic trioxide on subcutaneously implanted human gastric cancer in nude mice. [2010.04.15]

Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU. [2010.04]

Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. [2010.04]

Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. [2010.04]

External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature. [2010.04]

Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. [2010.04]

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. [2010.03.04]

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. [2010.02.20]

Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line. [2010]

Different pathways are involved in arsenic-trioxide-induced cell proliferation and growth inhibition in human keratinocytes. [2010]

Arsenic trioxide induces apoptosis in uveal melanoma cells through the mitochondrial pathway. [2010]

Immunotoxicity and biodistribution analysis of arsenic trioxide in C57Bl/6 mice following a 2-week inhalation exposure. [2009.12.15]

Preparation, characterization, in vivo and in vitro studies of arsenic trioxide Mg-Fe ferrite magnetic nanoparticles. [2009.12]

Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. [2009.11.01]

[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis] [2009.11]

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. [2009.11]

Darinaparsin: a novel organic arsenical with promising anticancer activity. [2009.11]

Isopathic treatment effects of Arsenicum album 45x on wheat seedling growth--further reproduction trials. [2009.10]

Arsenic trioxide inhibits metastatic potential of mouse hepatoma H22 cells in vitro and in vivo. [2009.10]

Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). [2009.10]

[Efficacy of arsenic trioxide for acute promyelocytic leukemia: a systematic review and meta-analysis.] [2009.09]

Subchronic exposure to arsenic trioxide-induced oxidative DNA damage in kidney tissue of mice. [2009.08.10]

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. [2009.08.01]

Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. [2009.07]

Effect of arsenic trioxide on renal functions and its modulation by Curcuma aromatica leaf extract in albino rat. [2009.07]

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). [2009.06.25]

Enhancement of esculetin on arsenic trioxide-provoked apoptosis in human leukemia U937 cells. [2009.06.15]

Arsenic trioxide attenuated the rejection of major histocompatibility complex fully-mismatched cardiac allografts in mice. [2009.06]

Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. [2009.06]

Comparing the relative oxidative DNA damage caused by various arsenic species by quantifying urinary levels of 8-hydroxy-2'-deoxyguanosine with isotope-dilution liquid chromatography/mass spectrometry. [2009.06]

Arsenic: a beneficial therapeutic poison - a historical overview. [2009.06]

[Effect of arsenic trioxide combined with aspirin on the growth of human gastric adenocarcinoma graft in nude mice] [2009.05]

Lead-, cadmium-, and arsenic-induced DNA damage in rat germinal cells. [2009.05]

A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. [2009.05]

Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration. [2009.04]

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. [2009.03.03]

Survival after a massive overdose of arsenic trioxide. [2009.03]

Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. [2009.03]

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. [2009.02.01]

Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. [2009.01.14]

[Effects of arsenic trioxide on human coronary smooth muscle cells: experiment in vitro] [2009.01.13]

Acute arsenic self-poisoning for suicidal purpose in a dentist: a case report. [2009.01]

Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. [2009.01]

Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. [2009.01]

Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. [2009]

Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. [2009]

Arsenic trioxide phosphorylates c-Fos to transactivate p21(WAF1/CIP1) expression. [2008.12.01]

Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. [2008.12]

What is the role of arsenic in newly diagnosed APL? [2008.12]

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. [2008.12]

Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. [2008.12]

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. [2008.11.01]

Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. [2008.11.01]

Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. [2008.11]

[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases] [2008.11]

Antitumor effects of arsenic trioxide in transformed human thyroid cells. [2008.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012